The critical need for defining preclinical biomarkers in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
The increasing number of afflicted individuals with late‐onset Alzheimer's disease (AD) poses significant emotional and financial burden on the world's population. Therapeutics designed to treat symptoms or alter the disease course have failed to make an impact, despite substantial investments by governments, pharmaceutical industry, and private donors. These failures in treatment efficacy have led many to believe that symptomatic disease, including both mild cognitive impairment (MCI) and AD, may be refractory to therapeutic intervention. The recent focus on biomarkers for defining the preclinical state of MCI/AD is in the hope of defining a therapeutic window in which the neural substrate remains responsive to treatment. The ability of biomarkers to adequately define the at‐risk state may ultimately allow novel or repurposed therapeutic agents to finally achieve the disease‐modifying status for AD. In this review, we examine current preclinical AD biomarkers and suggest how to generalize their use going forward.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 3×
“The new guidelines that emerged from the meeting added to and expanded on the existing diagnostic guidelines for dementia due to AD [10], MCI due to AD [9], and neuropathologic findings at autopsy that support a diagnosis of AD [20].”
BackgroundMethodSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 3×
“jected delays in disease onset by as little as 5 years, resulting from a successful therapeutic strategy, have the potential to reduce the Medicare costs of AD nearly in half [8].”
BackgroundInfluentialMR diffusion tensor spectroscopy and imaging
Basser, P. J., Mattiello, J., & LeBihan, D. (1994) · Biophysical Journal · doi:10.1016/s0006-3495(94)80775-1 · Cited by 5,970
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Greicius, M. D., Srivastava, G., Reiss, A. L., & Menon, V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308627101 · Cited by 3,684 · cited 1×
“These explicit DMN deviations have been suggested as biomarkers for AD [86,87].”
BackgroundHyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · cited 1×
“The new guidelines that emerged from the meeting added to and expanded on the existing diagnostic guidelines for dementia due to AD [10], MCI due to AD [9], and neuropathologic findings at autopsy that support a diagnosis of AD [20].”
BackgroundChronic traumatic encephalopathy in athletes: Progressive tauopathy after repetitive head injury
McKee, A. C., Cantu, R. C., Nowinski, C. J., Hedley-Whyte, E. T., Gavett, B. E., Budson, A. E., Santini, V. E., Lee, H.-S., Kubilus, C. A., & Stern, R. A. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181a9d503 · Cited by 2,295 · cited 12×
“Although EOAD has a genetic basis and has been closely tied to the amyloid hypothesis [2] of the disease, LOAD has genetic associations and probably results from a combination of environmental factors, genetic susceptibilities, and yet to be determined influences.”
ResultInfluential
Cited by
González-Reyes, R. E., Nava-Mesa, M. O., Vargas-Sánchez, K., Ariza-Salamanca, D., & Mora-Muñoz, L. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00427 · Cited by 527
Neff, R. A., Wang, M., Vatansever, S., Guo, L., Ming, C., Wang, Q., Wang, E., Horgusluoglu-Moloch, E., Song, W.-M., Li, A., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb5398 · Cited by 324
Amyloid blood biomarker detects Alzheimer's disease
Nabers, A., Perna, L., Lange, J., Mons, U., Schartner, J., Güldenhaupt, J., Saum, K., Janelidze, S., Holleczek, B., Rujescu, D., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708763 · Cited by 185
“…of this blood test is that Ab b-misfolding may be present in some persons without dementia and be absent in some AD patients; hence, false positives and false negatives are intrinsic to amyloid biomarkers (Yang et al, 2012; Fiandaca et al, 2014; Henriksen et al, 2014; Jansen et al, 2015).”
BackgroundWhen Does Alzheimer′s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225536 · Cited by 131
APP Function and Lipids: A Bidirectional Link
Grimm, M. O. W., Mett, J., Grimm, H. S., & Hartmann, T. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00063 · Cited by 104
“So, the identification of early AD-biomarkers with a high specificity and reliability is a central topic in AD research (Fiandaca et al., 2014).”
Background
Metadata
- Authors
- Fiandaca, M. S., Mapstone, M. E., Cheema, A. K., & Federoff, H. J.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2014-06
- Volume
- 10
- Issue
- 3S
- Pages
- S196-212
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W1965227180
- Cited by
- 131
- References
- 42
- FWCI
- 10.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The critical need for defining preclinical biomarkers in Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.jalz.2014.04.015
- The paper
- Fiandaca, M. S., Mapstone, M. E., Cheema, A. K., & Federoff, H. J. (2014). The critical need for defining preclinical biomarkers in Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2014.04.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.